BR112022002029A2 - Uso de sepiapterina e seus metabólitos para tratar exposição à radiação - Google Patents

Uso de sepiapterina e seus metabólitos para tratar exposição à radiação

Info

Publication number
BR112022002029A2
BR112022002029A2 BR112022002029A BR112022002029A BR112022002029A2 BR 112022002029 A2 BR112022002029 A2 BR 112022002029A2 BR 112022002029 A BR112022002029 A BR 112022002029A BR 112022002029 A BR112022002029 A BR 112022002029A BR 112022002029 A2 BR112022002029 A2 BR 112022002029A2
Authority
BR
Brazil
Prior art keywords
sepiapterin
radiation exposure
metabolites
treat radiation
treat
Prior art date
Application number
BR112022002029A
Other languages
English (en)
Portuguese (pt)
Inventor
Christopher Rabender
Eleonora Mezzaroma
Neil Smith
Ross Mikkelsen
Vasily Yakovlev
Original Assignee
Ptc Therapeutics Mp Inc
Univ Virginia Commonwealth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Mp Inc, Univ Virginia Commonwealth filed Critical Ptc Therapeutics Mp Inc
Publication of BR112022002029A2 publication Critical patent/BR112022002029A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
BR112022002029A 2019-08-05 2020-08-05 Uso de sepiapterina e seus metabólitos para tratar exposição à radiação BR112022002029A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962882937P 2019-08-05 2019-08-05
PCT/US2020/045026 WO2021026247A1 (en) 2019-08-05 2020-08-05 Use of sepiapterin and metabolites thereof to treat radiation exposure

Publications (1)

Publication Number Publication Date
BR112022002029A2 true BR112022002029A2 (pt) 2022-06-07

Family

ID=72148243

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022002029A BR112022002029A2 (pt) 2019-08-05 2020-08-05 Uso de sepiapterina e seus metabólitos para tratar exposição à radiação

Country Status (21)

Country Link
US (1) US20220273661A1 (https=)
EP (2) EP4454712A3 (https=)
JP (2) JP7642611B2 (https=)
CN (2) CN114555090B (https=)
AU (1) AU2020324435B2 (https=)
BR (1) BR112022002029A2 (https=)
CA (1) CA3146477A1 (https=)
DK (1) DK4009978T3 (https=)
ES (1) ES2994060T3 (https=)
FI (1) FI4009978T3 (https=)
HR (1) HRP20241653T1 (https=)
HU (1) HUE069012T2 (https=)
IL (1) IL290321B1 (https=)
LT (1) LT4009978T (https=)
MX (1) MX2022001535A (https=)
PL (1) PL4009978T3 (https=)
PT (1) PT4009978T (https=)
RS (1) RS66096B1 (https=)
SI (1) SI4009978T1 (https=)
SM (1) SMT202500089T1 (https=)
WO (1) WO2021026247A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA46973A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
FI3801536T3 (fi) 2018-05-30 2024-08-29 Ptc Therapeutics Mp Inc Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi
EP3801534B1 (en) 2018-05-30 2026-02-18 PTC Therapeutics MP, Inc. Treatment of phenylketonuria with sepiapterin
IL290321B1 (en) * 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
WO2005048926A2 (en) 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
KR20070084270A (ko) 2004-11-17 2007-08-24 바이오마린 파머수티컬 인크. 안정한 정제 제형물
TWI359019B (en) * 2006-08-14 2012-03-01 Merck Eprova Ag Use of folates for the prevention and treatment of
MX379061B (es) 2013-09-13 2025-03-04 Bioventures Llc Preparacion y uso de una composicion para la prevencion y mitigacion de los efectos de la radiacion.
CN106794197A (zh) 2014-10-02 2017-05-31 西托索尔本茨公司 经胃肠施用的多孔消化道吸着剂聚合物用于预防或治疗辐射诱导的黏膜炎、食管炎、小肠炎、结肠炎和胃肠急性放射综合征的用途
MA46973A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
AU2019277372B2 (en) 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
IL290321B1 (en) * 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment
CN110354133A (zh) * 2019-08-26 2019-10-22 鞍山市肿瘤医院 四氢生物蝶呤的应用及药物

Also Published As

Publication number Publication date
CN114555090A (zh) 2022-05-27
US20220273661A1 (en) 2022-09-01
EP4454712A3 (en) 2025-01-01
FI4009978T3 (fi) 2024-11-01
JP2025098011A (ja) 2025-07-01
EP4009978A1 (en) 2022-06-15
HUE069012T2 (hu) 2025-02-28
EP4009978B1 (en) 2024-09-25
ES2994060T3 (en) 2025-01-16
CN119837879A (zh) 2025-04-18
SI4009978T1 (sl) 2025-03-31
CA3146477A1 (en) 2021-02-11
RS66096B1 (sr) 2024-11-29
AU2020324435A1 (en) 2022-02-24
JP2022543655A (ja) 2022-10-13
IL290321B1 (en) 2026-04-01
LT4009978T (lt) 2024-11-25
HRP20241653T1 (hr) 2025-04-25
PL4009978T3 (pl) 2025-02-24
PT4009978T (pt) 2024-11-05
WO2021026247A1 (en) 2021-02-11
IL290321A (en) 2022-04-01
CN114555090B (zh) 2024-12-17
JP7642611B2 (ja) 2025-03-10
MX2022001535A (es) 2022-03-04
AU2020324435B2 (en) 2026-03-19
DK4009978T3 (da) 2024-10-14
SMT202500089T1 (it) 2025-03-12
EP4454712A2 (en) 2024-10-30

Similar Documents

Publication Publication Date Title
BR112022002029A2 (pt) Uso de sepiapterina e seus metabólitos para tratar exposição à radiação
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
BR112021008873A8 (pt) Formulação
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
BR112015018092A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
BR112016025009A2 (pt) anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície
BR112015018094A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
BR112015018087A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
BR112015020941A2 (pt) uso de derivados de pirazolopirimidina para o tratamento de distúrbios relacionados a pi3kdelta
BR112015021979A2 (pt) Anticorpos humanos para grem1
CO2018002568A2 (es) Acetamida tienotriazolodiazepinas y usos de las mismas
BR112014011925A2 (pt) mutações no receptor notch humano e seu uso
BR112021016833A2 (pt) Compostos com atividade indutora de ferroptose e métodos de seu uso
BR112017018160A2 (pt) uso do vírus vaccinia ankara modificado (mva) não replicante inativado como monoimunoterpia ou em combinação com agentes de bloqueio de pontos de verificação imunológica para tumores sólidos
CO2021017317A2 (es) Células seguras e invisibles para el sistema inmunitario
MX389545B (es) Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.
MX2022002954A (es) Anticuerpos anti-htra1 y metodos de uso de los mismos.
CL2020003118A1 (es) Régimen de dosificación para el tratamiento de trastornos relacionados con pi3k.
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
MX2024006768A (es) Compuestos y usos de los mismos.
CO2020014599A2 (es) Métodos para tratar cáncer
CO2022000270A2 (es) Inhibidores de enzimas

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]